论文部分内容阅读
目的探讨不同剂量米非司酮治疗围绝经期功能失调性子宫出血的可行性和必要性,以提高围绝经期功能失调性子宫出血患者的临床治疗效果。方法选取2012年1月-2014年1月在该院治疗的围绝经期功能失调性子宫出血患者40例为研究对象,根据随机双盲对照原则分为观察组和对照组各20例。观察组患者采取米非司酮12.5 mg/d口服治疗,对照组患者采取米非司酮6.25 mg/d口服治疗,对比两组患者的临床治疗效果及并发症的发生率。结果观察组的治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者子宫内膜厚度、激素(血清雌二醇、促黄体激素、孕酮)水平均明显低于对照组患者,两组比较,差异有统计学意义(P<0.05)。结论围绝经期功能失调性子宫出血患者应用米非司酮12.5 mg/d口服治疗,不仅可以提高治疗效果,而且还能减少子宫内膜厚度并降低体内激素水平,效果显著,值得临床应用。
Objective To investigate the feasibility and necessity of different doses of mifepristone in treating peri-menopausal dysfunctional uterine bleeding in order to improve the clinical therapeutic effect of patients with dysfunctional uterine bleeding in perimenopausal period. Methods Forty patients with peri-menopausal dysfunctional uterine bleeding who were treated in our hospital from January 2012 to January 2014 were enrolled in this study. According to the principle of random double-blind control, 20 cases were divided into observation group and control group. The patients in the observation group were treated with mifepristone 12.5 mg / d orally, while the patients in the control group were orally taken 6.25 mg / d of mifepristone. The clinical effects and the incidence of complications were compared between the two groups. Results The total effective rate of observation group was higher than that of control group (P <0.05). The endometrial thickness and the levels of hormones (serum estradiol, luteinizing hormone and progesterone) in observation group were significantly lower In the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion Oral administration of mifepristone 12.5 mg / d in patients with climacteric dysfunctional uterine bleeding can not only improve the therapeutic effect, but also reduce the thickness of the endometrium and reduce the hormone levels in the body, which is effective and worthy of clinical application.